As part of the collaboration, the Phase II trial investigating Gate’s zelquistinel will use Beacon’s Dreem 3S headband device and neuro biomarker platform to conduct exploratory EEG and sleep ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results